Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (41-50 of 284) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2005
Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biologyPasi A Jänne, Jeffrey A Engelman, Bruce E Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerPeter S Hammerman, Pasi A Jänne, Bruce E Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2012
Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnosticsDavid R Parkinson, Bruce E Johnson, George W Sledge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Gefitinib for recurrent non-small-cell lung cancer: all things are not created equalSuzanne E Dahlberg, Robert J Gray, Bruce E Johnson
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Imatinib in small cell lung cancerJean-Charles Soria, Bruce E Johnson, Thierry Le Chevalier
Radiology|March 26, 2014
State of the art: Response assessment in lung cancer in the era of genomic medicineMizuki Nishino, Hiroto Hatabu, Bruce E Johnson, et al.
Oncology|July 16, 2005
Therapeutic targeting of multiple signaling pathways in malignant pleural mesotheliomaToru Mukohara, Gabriel Civiello, Bruce E Johnson, et al.
Cancer Research|September 18, 2002
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesotheliomaPasi A Jänne, Michele L Taffaro, Ravi Salgia, et al.
Journal of the National Cancer Institute|December 22, 2018
Race, Poverty, and Initial Implementation of Precision Medicine for Lung CancerKenneth L Kehl, Christopher S Lathan, Bruce E Johnson, et al.
JCO Precision Oncology|January 20, 2022
Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center CohortVivek A Upadhyay, Bruce E Johnson, Adam B Landman, et al.
Pageof 29

Showing results (41-50 of 284) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2005
Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biologyPasi A Jänne, Jeffrey A Engelman, Bruce E Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerPeter S Hammerman, Pasi A Jänne, Bruce E Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2012
Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnosticsDavid R Parkinson, Bruce E Johnson, George W Sledge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Gefitinib for recurrent non-small-cell lung cancer: all things are not created equalSuzanne E Dahlberg, Robert J Gray, Bruce E Johnson
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Imatinib in small cell lung cancerJean-Charles Soria, Bruce E Johnson, Thierry Le Chevalier
Radiology|March 26, 2014
State of the art: Response assessment in lung cancer in the era of genomic medicineMizuki Nishino, Hiroto Hatabu, Bruce E Johnson, et al.
Oncology|July 16, 2005
Therapeutic targeting of multiple signaling pathways in malignant pleural mesotheliomaToru Mukohara, Gabriel Civiello, Bruce E Johnson, et al.
Cancer Research|September 18, 2002
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesotheliomaPasi A Jänne, Michele L Taffaro, Ravi Salgia, et al.
Journal of the National Cancer Institute|December 22, 2018
Race, Poverty, and Initial Implementation of Precision Medicine for Lung CancerKenneth L Kehl, Christopher S Lathan, Bruce E Johnson, et al.
JCO Precision Oncology|January 20, 2022
Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center CohortVivek A Upadhyay, Bruce E Johnson, Adam B Landman, et al.
Pageof 29